Partner Judy Waltz and Jack Haake were quoted in an article, “Supreme Court Ends Nursing Home Provider Agreement Dispute,” covering the outcome of the Supreme Court’s decision to not stop Medicare and Medicaid provider agreements to companies going bankrupt.
Haake explained that “the practical outcome of the Supreme Court’s decision is that bankruptcy courts in the Eleventh Circuit are bound by precedent established by the Eleventh Circuit that they do not have jurisdiction over termination of provider agreements where administrative remedies have not been exhausted.”
Waltz seconded Haake’s statement and also explained, “that may be a significantly different jurisdictional analysis from a situation involving more traditional bankruptcy issues like a dispute over a claim or dispute over a collection mechanism in bankruptcy.”
Haake explained that “the practical outcome of the Supreme Court’s decision is that bankruptcy courts in the Eleventh Circuit are bound by precedent established by the Eleventh Circuit that they do not have jurisdiction over termination of provider agreements where administrative remedies have not been exhausted.”
Waltz seconded Haake’s statement and also explained, “that may be a significantly different jurisdictional analysis from a situation involving more traditional bankruptcy issues like a dispute over a claim or dispute over a collection mechanism in bankruptcy.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”